Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17637697 | 0.91 | L3MBTL1 (0.41) | L3MBTL1TDP1SMN1; SMN2NPSR1RXFP1 | |
| SCHEMBL16925689 | 0.89 | CDC25A (0.41) | L3MBTL1TDP1SMN1; SMN2NPC1MAPK1 | |
| SCHEMBL17246135 | 0.88 | MAPT (0.42) | L3MBTL1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL16925708 | 0.86 | KMT2A (0.40) | L3MBTL1TDP1SMN1; SMN2NPSR1RXFP1 | |
| SCHEMBL9889811 | 0.86 | MAPT (0.45) | L3MBTL1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL18120468 | 0.84 | AHR (0.41) | L3MBTL1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL17637983 | 0.84 | NPC1 (0.41) | L3MBTL1TDP1SMN1; SMN2NPSR1RXFP1 | |
| SCHEMBL24409767 | 0.84 | CHRNA7 (0.46) | L3MBTL1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19472211 | 0.84 | CA9 (0.40) | L3MBTL1TDP1SMN1; SMN2NPSR1RXFP1 | |
| SCHEMBL9892678 | 0.83 | KDM4E (0.42) | L3MBTL1SMN1; SMN2NPSR1RXFP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197887-B1 | HETEROCYCLIC COMPOUNDS WITH BENZO[C]COUMARIN-STRUCTURES | MERCK PATENT GMBH (DE) | 2020-09-23 | — | — | EP | disclosed |
| US-10377766-B2 | Heterocyclic compounds with benzo(c)coumarin-structures | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-20170298077-A1 | HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES | MERCK PATENT GMBH (DE) | 2017-10-19 | — | — | US | disclosed |
| US-20170298077-A1 | HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES | MERCK PATENT GMBH (DE) | 2017-10-19 | — | — | US | disclosed |
| WO-2016045769-A1 | HETEROCYCLIC COMPOUNDS WITH BENZO[C]COUMARIN-STRUCTURES | MERCK PATENT GMBH (DE) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298077-A1 | HETEROCYCLIC COMPOUNDS WITH BENZO(C)COUMARIN-STRUCTURES | NISCH, SIRT3, NQO1 | L3MBTL1 3462/4885TDP1 2897/4885SMN1; SMN2 4716/4885 |
| US-10377766-B2 | Heterocyclic compounds with benzo(c)coumarin-structures | NISCH, SIRT3, NQO1 | L3MBTL1 3462/4885TDP1 2897/4885SMN1; SMN2 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.